anti-CLL-1/anti-CD38 CAR T cells

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) C-type-lectin-like molecule-1 (CLL-1; CLL1; C-type lectin domain family 12 member A; CLEC12A) and CD38, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CLL-1/anti-CD38 CAR T cells specifically and simultaneously target and bind to CD38- and CLL-1-expressing tumor cells. This induces selective toxicity in CD38- and CLL-1-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. CLL-1, a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed in leukemic stem cells (LSCs) and plays an important role in disease progression and relapse for myeloid malignancies.